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ABSTRACT
Background: Identification of HIV-1 genomes responsible for establishing clinical infection in 
newly infected individuals is fundamental to prevention and pathogenesis research. Processing, 
storage, and transportation of the clinical samples required to perform these virologic assays in 
resource-limited settings requires challenging venipuncture and cold chain logistics. Here, we 
validate the use of dried-blood spots (DBS) as a simple and convenient alternative to collecting 
and storing frozen plasma. 
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Methods: We performed parallel nucleic acid extraction, single genome amplification (SGA), 
next generation sequencing (NGS), and phylogenetic analyses on plasma and DBS. 
Results: We demonstrated the capacity to extract viral RNA from DBS and perform SGA to infer 
the complete nucleotide sequence of the transmitted/founder (TF) HIV-1 envelope gene and full-
length genome in two acutely infected individuals. Using both SGA and NGS methodologies, we 
showed that sequences generated from DBS and plasma display comparable phylogenetic pat-
terns in both acute and chronic infection. SGA was successful on samples with a range of plasma 
viremia, including samples as low as 1,700 copies/ml and an estimated ~50 viral copies per blood 
spot. Further, we demonstrated reproducible efficiency in gp160 env sequencing in DBS stored at 
ambient temperature for up to three weeks or at -20ºC for up to five months. 
Conclusions: These findings support the use of DBS as a practical and cost-effective alternative to 
frozen plasma for clinical trials and translational research conducted in resource-limited settings.
Keywords: dried blood spots, single genome sequencing, transmitted/founder virus, viral diversi-
ty, resource-limited settings
INTRODUCTION
Accurate identification and characterization of the virus that establishes productive clinical HIV-1 
infection, or the transmitted/founder (TF) virus, is fundamentally important to many areas of 
HIV research. The exact identification of TF HIV-1 genomes was first enabled by single genome 
amplification strategies (SGA) [1-7], which utilize endpoint dilution amplification of plasma viral 
HIV-1 RNA to accurately and proportionally represent full-length genes or genomes from the 
complex circulating virus quasispecies. SGA has been an enabling technology for TF identifica-
tion because it allows linkage between distant sites by sequencing of longer continuous templates 
and minimizes in vitro errors associated with bulk polymerase chain reaction (PCR) techniques 
[4, 8]. SGA applied to acutely HIV-1 infected cohorts enabled the enumeration and characteriza-
tion of TF viruses and demonstrated the strict transmission bottleneck existent in heterosexual, 
men who have sex with men (MSM), and injection drug user (IDU) transmission [1-5, 9], and the 
immune pressures at play in acutely infected individuals [7, 10, 11]. More recently, identification 
of the TF viruses that break through in clinical vaccine trials has enabled genetic and phenotypic 
sieve studies [9, 12-17]. By comparing features of the TF viruses establishing infection in vaccine 
recipients to those of placebo recipients, sieve analyses have identified properties of the specific 
viruses blocked (or “sieved”) by vaccine-induced immune pressure. Examples include CD8 T-cell 
epitopes in conserved viral structural proteins [15] and antibody targets in envelope [14]. In ad-
dition, SGA analysis of the breakthrough rebound viruses that arise after or during clinical trials 
of curative strategies [18, 19] has the potential to elucidate the mechanisms of successful virus 
suppression or eradication and the pathways that viruses utilize to escape. For example, SGA and 
phenotypic characterization of breakthrough viruses emerging during or after passive adminis-
tration of broadly neutralizing antibodies (bNAbs) allows accurate identification of neutralization 
escape variants and their pathways of developing resistance [20]. The HIV-1 field is currently 
testing multiple novel prevention strategies in large clinical trials, including vaccines, passively 
administered bNAbs, pre-exposure prophylaxis, and microbicides. For each of these trials, iden-
tifying and analyzing the breakthrough TF viruses for relevant properties (e.g., drug resistance, 
neutralization sensitivity, linked transmission networks, etc.) will be of paramount importance to 
the interpretation of trial results. 
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Accurate identification of TF or breakthrough viruses requires frequent venipuncture to obtain 
plasma samples near the time of transmission or rebound and places significant burdens on trial 
subjects and clinical staff (repeated venipuncture) and infrastructure (cold storage and shipping 
of many plasma samples). For these critically important trials, especially those conducted in re-
source-limited settings, simple and cost-effective protocols are needed. The capacity to use dried 
blood spots (DBS) to identify and study the breakthrough TF viruses, in lieu of stored plasma 
samples, would greatly facilitate cost-effective clinical trials. 
The past several years have yielded multiple demonstrations of the feasibility of DBS as an alterna-
tive clinical specimen for HIV-1 diagnosis, viral load quantification, and drug-resistance geno-
typing [21-27]. The World Health Organization has identified DBS as the sample type for HIV 
resistance genotyping in settings without the capacity to collect, store, and transport plasma [28]. 
DBS have important advantages over plasma, particularly in resource-limited settings, as they are 
simple to collect, represent non-hazardous material, and require substantially less strict cold stor-
age, in terms of both space and temperature for storage and transportation [21]. While studies of 
paired DBS and plasma samples have reported concordant results for HIV-1 genotyping and viral 
load quantification [21, 22, 26, 27], no previous study has demonstrated the feasibility of using 
DBS to examine HIV-1 envelope (env) gene diversity in acute and chronic infection or identify the 
TF env or full-length genome during primary HIV-1 infection. Recently, investigators presented 
an in-house SGA assay to amplify HIV-1 DNA from DBS obtained from infant heel-prick blood 
in field settings in Lusaka, Zambia [29], but no D Lusaka, Zambia NA sequencing data were 
included. Here, we examined the feasibility of using DBS to delineate HIV env diversity in acute 
and chronic infection and to identify the TF envs and complete genomes responsible for establish-
ing productive clinical infection. We found that SGA from DBS provided equivalent sequencing 
results compared to those derived from plasma, and sufficient efficiency to merit its consideration 
in future clinical trials. 
MATERIAL AND METHODS
Patients. Peripheral blood samples were obtained from 9 subjects with either acute/early (n = 2) 
or chronic (n = 7) HIV infection. All patients provided written informed consent for blood col-
lection and subsequent analysis, under protocols approved by the Institutional Review Board of 
the University of Alabama at Birmingham. Clinical and laboratory staging of HIV infection was 
estimated by a battery of commercial assays, including HIV-1 enzyme immunoassay, Western 
blot, and quantitative polymerase chain reaction. 
DBS and plasma collection. Whole blood was collected by venipuncture from HIV-infected 
individuals in tubes containing acid-citrate-dextrose (ACD) as an anticoagulant. Plasma was sep-
arated within 6 hours of the time of blood collection by centrifugation, aliquoted in clean tubes, 
and stored at −80ºC. DBS were prepared at the University of Alabama at Birmingham Center for 
AIDS Research laboratories by pipetting 50 µl of freshly collected ACD whole blood in each of 5 
circles of a Whatman 903 card (Whatman Inc., Florham Park, NJ). Cards from each patient were 
then allowed to air-dry in a flat position at ambient temperature for 2-4 hours, followed by short-
term storage at ambient temperature (~23ºC) in a sealed plastic bag along with silica gel desiccant 
sachets. After short-term storage, DBS enclosed in sealed bags were transferred to a non-frost-
free −20ºC freezer for long-term storage.
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Nucleic acid extraction from plasma and DBS. Individual 50 µl DBS were submitted to RNA 
extraction by two techniques based on DBS card manufacturer instructions. For technique 1, DBS 
were incubated with 400 µl of RNase-free water for 30 minutes at 37ºC, followed by transfer of the 
reddish fluid to a clean microcentrifuge tube containing 1 ml of TRIzol reagent (Life Technolo-
gies). In technique 2, DBS were directly incubated in 1 ml of TRIzol reagent (Life Technologies) 
for 30 minutes at room temperature, followed by transfer of the TRIzol-sample mix to a clean 
microcentrifuge tube. Plasma samples were similarly analyzed in two ways. For the first meth-
od, 1 ml of TRIzol was mixed and incubated with 25 µl of liquid plasma (the estimated average 
amount of plasma dried in 50 µl blood spots) for 30 minutes at room temperature. At the end of 
the incubation, RNA was extracted from the TRIzol containing samples following the manufac-
turer’s instructions (Life Technologies). For the second method, RNA was extracted from 25 µl of 
liquid plasma using a QIAamp viral RNA mini kit and following the manufacturer’s instructions 
(QIAGEN, Valencia, CA), which served as a reference RNA standard to estimate the efficiency of 
SGA assays performed in all other RNA extraction procedures. Total RNA was isolated via pre-
cipitation, washed, and resuspended in 30 µl of RNase-free water (for procedures using TRIzol) 
or 60 µl of elution buffer (for the QIAGEN protocol), as per the manufacturers’ instructions. RNA 
preparations were used either immediately for cDNA synthesis or stored at −80ºC. 
cDNA synthesis. Reverse transcription was carried out with SuperScript III, using the protocol 
recommended by the manufacturer (Invitrogen Life Technologies, Carlsbad, CA) as previously 
described [4-6]. Briefly, 15 µl of nucleic acid extract from either plasma or DBS was reverse-tran-
scribed in a final volume of 40 µl of 1x reverse transcription buffer, 5 mM dithiothreitol, 0.5 mM 
of each deoxynucleoside triphosphate (dNTPs), 0.25 µM antisense primer, 2 units/µl RNase in-
hibitor, and 10 units/µl SuperScript III. Reverse primer sequences to generate cDNAs for env, 5′- 
and 3′-half genome amplification have been previously published [4, 7]. Reactions were incubated 
at 50ºC for 60 min, followed by an additional hour at 55ºC. At the end of the incubation, reactions 
were stopped by heat (70ºC for 15 min), followed by RNaseH digestion at 37ºC for 20 min. Tubes 
containing cDNA were then immediately used for SGA or stored at −80ºC. 
Single genome amplification and sequencing. To amplify full-length env genes, half-genomes 
and near full-length genomes (9-Kb), cDNA was endpoint diluted to an estimated single copy 
per well, followed by nested PCR using SGA procedures described previously [4, 6]. Primers were 
slightly different to amplify the 5′-half fragment for this study, as indicated below. Briefly, first- 
and second-round PCR were carried out similarly in 20 μl reactions containing 1x High Fidelity 
Platinum PCR buffer, 2 mM MgSO4, 0.2 mM of each dNTP, 0.2 μM each of sense and antisense 
primers, and 0.025 units/μl platinum Taq High Fidelity polymerase (Invitrogen, Carlsbad, CA) 
in MicroAmp optical 96-well reaction plates (Thermo Scientific, Foster City, CA) and sealed with 
ABI MicroAmp adhesive film. 5′-half genomes were amplified in the first-round PCR using sense 
primer RVF1 5′-GGG TCT CTC TGG TTA GAC CAG ATC-3′ (nt 454-477 HXB2) and antisense 
primer B5R1 5′-CTT GCC ACA CAA TCA TCA CCT GCC AT-3′ (nt 5,052–5,077 HXB2) using 
the following PCR conditions: 94ºC for 2 minutes followed by 35 cycles of 94ºC for 15 seconds; 
55ºC for 30 seconds; and 68ºC for 5 minutes, with a final extension of 68ºC for 10 minutes. Next, 
1 or 2 μl of first-round product was transferred to a final 20 μl PCR reaction containing sense 
primer RVF20 5′-GAG CCT GGG AGC TCT CTG GCT A (nt 479–500 HXB2) and antisense 
primer B5R2 5′- CAA TCA TCA CCT GCC ATC TGT TTT CCA TA-3′ (nt 5,040–5,068 HXB2), 
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and a ~5 Kb fragment was amplified using the same reagent mix as the first round. PCR con-
ditions were the same as the first round, but with a total of 45 PCR cycles. PCR positive wells 
containing amplicons of the predicted size by agarose gel electrophoresis were selected for DNA 
sequencing. Sanger sequencing was performed in a 3730xl DNA Analyzer using BigDye Termi-
nator v.3.1 chemistry following the manufacturer’s protocols (Thermo Scientific, Carlsbad, CA). 
Amplicons were sequenced bidirectionally and chromatograms were edited using Sequencher 
program, version 5.1 (Gene Codes Corporation, Ann Arbor, MI). PCR products displaying mixed 
bases at one or multiple nucleotide positions were excluded from further analysis. 
Efficiency comparisons. The estimated efficiency of the method to amplify HIV-1 from single 
molecules was based on the number of amplicons derived from a unit of plasma equivalents pres-
ent in paired DBS and plasma extracts. We assigned 100% efficiency to HIV amplification from 
frozen plasma extracted with the QIAamp viral RNA mini kit. The efficiency in DBS was then 
calculated using the number of amplicons derived from plasma equivalents present in the DBS 
extract after considering that approximately half the volume of the 50 µl of whole blood spotted 
on the filter paper is plasma. 
Next generation 454 deep sequencing. DBS vRNA from samples T8250 and N8261 were ampli-
fied using nested reverse transcriptase PCR (RT-PCR) over three overlapping regions of the ge-
nome (gag, pol, and a 3′ genomic half). Primer sequences and PCR conditions are available upon 
request. First-round RT-PCR was performed using the Superscript III one-step RT-PCR system 
with Platinum Taq DNA polymerase with High Fidelity (Invitrogen, Carlsbad, CA). Each RT-
PCR reaction was composed of 10 μl of RNA, 25 μl of 2x reaction mix (buffer, deoxynucleoside 
triphosphate, and MgSO4), 0.4 µM of forward and reverse primers and 1 μl of enzyme mix, and 
water. Takara Ex Taq DNA polymerase Hot Start enzyme (Takara Bio Inc., Shiga, Japan) was used 
for the second-round PCR using 2 μl of round 1 product and 0.6 µM of each primer according to 
the manufacturer’s directions. For post-PCR quality control purposes, the products were run on 
precast 1% agarose E-gels. Positive PCR products were purified using the QIAquick PCR Purifica-
tion Kit (Qiagen) or the PureLink Quick Gel Extraction Kit (Invitrogen) and concentrations were 
determined using the Thermo Scientific Nanodrop 8000 spectrophotometer (Nanodrop Prod-
ucts). Amplifications from the same subject were pooled with concentration ratios of gag: pol: 3′ 
half being 1:1:3.
Purified PCR products from each sample were pooled in equimolar ratios, fragmented using the 
transposon-mediated Nextera DNA Sample Prep Kit (Illumina) following the manufacturer’s 
protocol, and purified with a DNA Clean and Concentrator Kit (Zymo Research). Adapters and 
barcodes were added by limited-cycle PCR (Nextera). Small fragments were removed following 
Roche’s recommended size selection protocol and quantified using a Promega Quantiflor-ST 
fluorometer. After quantification, barcoded samples were pooled at a final concentration of 10^7 
molecules/μl to create the library for sequencing on the GS Junior 454 Genome Sequencer (Roche 
Diagnostics). Emulsion PCR, breaking, and DNA sequencing were performed according to the 
manufacturer’s protocols for Lib-L (Roche Diagnostics). Resulting sequence reads were then 
cleaned and assembled into a de novo consensus using AV454 and VICUNA [30, 31]. Reads were 
first clustered to form contigs using min hashes and an inexact string matching based search to 
infer similarity. Contigs were validated by iteratively aligning each constituent read to the consen-
sus, and then aggressively merged to form a de novo consensus assembly of the viral population. 
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The reads were then corrected for systematic 454 errors such as homopolymer indels and car-
ry-forward/incomplete extensions and aligned to the consensus assembly using the previously de-
veloped software RC454 [30] with a variant calling performed by V-Phaser [32]. Briefly, V-Phaser 
uses phase and quality filtering with a probability model that recalibrates quality scores for indi-
vidual bases to iteratively refine probabilities and to define the threshold required to statistically 
call variants in the presence of errors with high specificity and high sensitivity [32]. Analyses were 
further subjected to manual inspection to identify and discard any sequencing artifacts.
Phylogenetic analysis. SGA-derived env nucleotide sequences from each subject were aligned us-
ing ClustalW, and manually adjusted [33]. Intrapatient env diversity was determined by pairwise 
comparison of sequences using uncorrected sequence distances. For each subject, a maximum 
likelihood (ML) phylogenetic tree was inferred using PhyML, version 3.0 [34], and phylogenetic 
support was based on 100 bootstrap replicates. The genetic identity of TF env genes in individ-
uals with recent infection was inferred as described previously [4]. APOBEC-associated G-to-A 
hypermutated sequences were excluded from analysis in the inference of the TF env sequence ac-
cording to the Los Alamos National Laboratory (LANL) HIV Sequence Database tool Hypermut 
2.0 [35]: http://www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html. Highlighter 
analysis of SGA sequences was performed using the LANL Highlighter tool: http://www.hiv.lanl.
gov/content/sequence/HIGHLIGHT/highlighter_top.html. Poisson-fitter analyses were per-
formed to determine whether env sequences conformed to predictions of a mathematical model 
of random viral evolution and to estimate the time to most recent common ancestor (MRCA) or 
the minimum number of days required to explain the observed within-patient HIV-1 sequence 
diversification from a single common ancestor sequence. This analysis was done using the Pois-
son-Fitter tool from the LANL (http://www.hiv.lanl.gov/content/sequence/POISSON_FITTER/
poisson_fitter.html), as previously described [4, 36].
Statistical analysis. Evidence of statistical compartmentalization was assessed using programs 
implemented by HyPhy software [37] including the Slatkin-Maddison (SM) test, which compares 
the minimum number of intercompartmental migration events to the frequency distribution of 
migration events in 1,000 randomized trees [38]. Two-sample tests were performed to compare 
intra-patient sequence diversity between DBS vs plasma viral populations using the DIVEIN web 
tool (http://www.ncbi.nlm.nih.gov/pubmed/20569214) [39] Correlations of method efficiency 
and viral load were performed using Spearman’s rank test. Nonparametric statistics were em-
ployed due to the small number of env sequences that were amplified from the DBS and plasma of 
some subjects. Statistical significance was defined for P values of < 0.05.
Nucleotide sequence accession numbers. All SGA sequences determined in this study were de-
posited in GenBank under accession numbers KU901727–KU901998. Deep sequencing data are 
available in the NCBI sequence read archive under the accession number SRA307377. 
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Table 1. Study subjects characteristics and number of SGA-derived env sequences. a.  Subject was previous-
ly on ART, but had been off ART for > 3 months prior to 12/28/11 sample.
Subject HIV status
Viral load  
(copies/ml)
Sample date
Antiretroviral 
treatment
DBS-de-
rived env 
sequences
Plasma-derived 
env sequences
A8110 Chronic   1,464,000 12/28/11 Naive 16 14
K8072 Chronic      156,000 02/15/12 Naive 16   8
T4590 Chronic      155,000 12/15/11 Naive 10 15
T8107 Chronic        26,300 02/15/12 Naive   8 11
J7180 Chronic        15,800 01/18/12 Naive   9 10
J6161 Chronic          2,200 01/04/12 Naive   9   6
F6817 Chronic          1,710 12/28/11 Experienceda   4 12
T8250 Acute 13,400,000 04/24/12 Naive 21 21
N8261 Acute 22,450,000 05/17/12 Naive 11 12
RESULTS
Performance characteristics of the viral RNA extraction and SGA of HIV-1 from DBS. To 
begin, we examined our capacity to isolate intact HIV-1 RNA for endpoint dilution PCR am-
plification of gp160 HIV-1 env from DBS stored at ambient temperatures for up to 3 weeks (21 
days). We studied samples from 9 HIV-1-infected subjects (Table 1) and determined the number 
of gp160 sequences that could be amplified by standard SGA after TRIzol-based extraction (see 
methods) from a single DBS. This method was chosen based on DBS card recommendations, 
to isolate RNA preferentially over proviral DNA, to improve yields with a non-column-based 
isolation method, and to avoid unknown reagents in the final elution buffer that might affect 
subsequent PCR reactions [40]. We estimated individual blood spots contained between ~50 and 
561,250 copies of HIV-1 RNA. This calculation was based on plasma viral load measurements for 
the 9 samples, which ranged from 1,710 to 22,450,000 copies/ml, the 50 µl quantity of blood per 
DBS, and the assumption that approximately 50% of whole blood volume is plasma. Extracted 
RNA underwent cDNA synthesis and endpoint dilution PCR and yielded reasonable numbers of 
gp160 env genes from each DBS (range 4-21 env sequences, median 10 per DBS) (Table 1). No-
tably, even DBS from subjects with the lowest viral loads (1,170 for F6817 and 2,200 for J6161) 
produced multiple amplicons per single DBS (Table 1). This number of gp160 env sequences 
from a single DBS suggests that the 5 DBS contained on commercially available cards could yield 
between 20 and > 100 sequences.
Notably, there was no correlation between the viral load of the sample and the efficiency of SGA 
from DBS, as determined by Spearman correlation test (r: −0.220, P> 0.05). Indeed, similar env 
amplification efficiencies were observed for DBS RNA extracted with TRIzol-alone from subjects 
T8250 (14.1%), T4590 (11.8%), T8107 (11.2%), and F6817 (8.3%) despite their broad range of 
viral loads (range: 1,710–13,400,000 copies/ml) (Table 2).
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Upon determining that we could amplify multiple intact gp160 env sequences, we next tested the 
efficiency of vRNA extraction from DBS compared with standard plasma viral RNA extraction 
methods. We compared DBS RNA extraction protocol to our gold standard procedure to extract 
vRNA from frozen plasma by automated commercial kit (QIAGEN QIAamp viral RNA mini kit). 
Of note, when tested in 9 plasma specimens, vRNA extraction by the TRIzol reagent protocol 
was substantially less efficient than the Qiagen protocol; approximately half the number (median 
52.8%) of plasma SGA-derived env sequences were obtained by TRIzol compared to the QIAGEN 
protocol. We next compared TRIzol extraction from DBS to the QIAGEN protocol’s automated 
extraction from plasma, which yielded a median of 11.2% as many sequences by volume (range 
1–41.0%). Alternate extraction protocols, including using water coupled with TRIzol RNA isola-
tion reagents, were less efficient, with a median of 4.6% (range 0.1–26.7%) (Table 2). 
Table 2. Effect of DBS storage time and temperature and extraction method on SGA efficiency.
RNA integrity is a critical factor in PCR amplification efficiency, and HIV-1 RNA spotted on 
filter paper is well documented to be prone to degradation, but the rate of degradation reported 
has varied by study, environmental conditions, and desired application [21]. We evaluated SGA 
yields from DBS stored for different lengths of time at ambient temperature and −20ºC. As seen 
in Table 2, short-term storage of DBS from 1 to 20 days at ambient temperature supported the 
generation of multiple SGA env amplicons. As predicted, SGA yields decreased with increased 
storage at ambient temperatures. Spearman rank correlation analysis showed a significant inverse 
correlation between DBS storage time and assay efficiency (r = −0.0703, P = 0.027). As shown in 
Table 2, DBS stored for either 1 or 6 days at room temperature had the highest env amplification 
efficiencies (see J6161 and K8072), whereas DBS stored for 18 days (N8261) had lesser amplifica-
tion efficiencies. Further, a DBS stored for 24 days at room temperature failed to generate any full-
length gp160 env amplicons despite a viral load of 29,920 copies/ml in an acutely infected subject, 
though amplification of multiple short fragments (~400 bp) was possible (data not shown). 
% efficiencies in DBS after 
short-term storage at ambient 
temperature
Subsequent transfer of DBS 
to -20ºC for long term stor-
age
Sample 
ID
Days DBS 
were kept 
at ambient 
temperature
Estimated HIV-1 
copies per DBSa
Plasma 
TRIzol  
efficiency 
(%)
DBS TRIzo-
lalone ex-
traction
DBS wa-
ter-TRIzol 
extraction
Storage time 
at -20ºC 
(months)
J6161 1 55 66.7 41.0 26.7
K8072 6 3,900 52.8 33.0 4.6 3.4 88.9
T8107 6 658 53.6 11.2 5.4 3.4 40.0
F6817 7 43 22.7 8.3 0.0 5.0 83.3
A8110 7 36,600 56.3 3.3 2.0 5.0 25.0
J7180 7 395 14.6 5.8 8.1
T8250 7 335,000 18.8 14.1 0.9
N8261 18 561,250 0.2 1.0 0.1
T4590 20 3,875 88.5 11.8 8.2
Median 7 3,875 52.80 11.20 4.60 3.0 19.4
Pathogens and Immunity - Vol 1, No 1
www.PaiJournal.com
137
Finally, we tested the capacity to preserve vRNA integrity when DBS were promptly (within 1-20 
days) frozen. For five subjects, DBS were stored at −20ºC for 3-5 months (Table 2). In each of 
these samples, viral RNA integrity was largely preserved, allowing successful amplification of 
full-length env genes with only modestly reduced efficiency (19–89%) when compared to baseline 
DBS (Table 2). 
Figure 1. HIV-1 env sequences derived from DBS are genetically heterogeneous and phylogenetically 
indistinguishable from plasma variants. Maximum likelihood phylogenetic analyses are shown for gp160 
HIV-1 env nucleotide sequences amplified by SGA from DBS (red circles) and plasma (blue squares) from 
seven chronically HIV-infected subjects (A to G). A single env sequence from subject T4590 (C) was 
excluded due to a large deletion. Numerals at nodes indicate approximate likelihood ratio test values of 
≥ 0.73. The scale bar represents the number of nucleotide substitutions per site. 
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SGA-derived HIV-1 env sequences from chronically infected subjects are phylogenetically similar 
in paired DBS and plasma samples. To determine the capacity of DBS to replace plasma as a sam-
ple platform for SGA, we compared the gp160 env sequences generated from each sample source 
in a panel of HIV-1 infected subjects. We amplified 228 full-length HIV-1 env genes (range 15-42, 
median 23 sequences per subject) from paired plasma and DBS samples obtained from 7 subjects 
with chronic HIV-1 infection who were off antiretroviral therapy (ART) (Fiebig stage VI; n = 6 
antiretroviral treatment naïve subjects and n = 1 subject with previous ART experience) (Table 
1). The subjects had plasma viral loads ranging from 1,710 to 22,450,000 copies/ml, allowing us 
to test a broad range of input HIV-1 viral loads. We performed RNA extraction, cDNA synthesis 
and SGA from the DBS and plasma samples and compared the SGA-derived sequences phyloge-
netically (Figure 1). For these chronically infected subjects, maximum likelihood phylogenetic 
analyses showed that DBS env sequences were phylogenetically heterogeneous and indistinguish-
able from those derived from plasma; that is, DBS env sequences were interspersed among plasma 
env sequences in phylogenetic trees (Figure 1). As has been previously reported in chronic HIV-1 
quasispecies, clusters of identical or near-identical sequences were noted in three chronically 
infected subjects (Figure 1D, E, and F), suggesting recent clonal expansion of some variants [41, 
42]. In two subjects (Figure 1 D, E), these identical sequences were derived from DBS and plasma 
sources, reinforcing the idea that comparable populations were sequenced by the different meth-
ods. To test for bias associated with DBS vs plasma source, we tested for differences in viral diver-
sity and compartmentalization (Table S1). Intra-patient env sequence diversity was not signifi-
cantly different in any individual when tested by a two-sample test for sequence diversity. Using 
a phylogenetically-based Slatkin-Maddison test to investigate whether viruses from DBS had any 
evidence of compartmentalization, we compared the minimum possible number of intercompart-
mental migration events to the frequency distribution of migration events in 1,000 randomized 
trees [35], and found that none of the 7 chronically HIV-infected and 2 acutely infected subjects 
examined showed statistical evidence of compartmentalization in DBS. Last, phylogenetic anal-
ysis of all env sequences demonstrated no evidence of cross-contamination between samples, as 
each subject’s sequences clustered in separate branches of the tree with inter-strain diversities 
typically observed for subtype B viruses (Figure S1). 
Table 3. Statistics and mathematical model estimates of the most recent common ancestor (MRCA) of 
HIV env sequences derived from DBS and plasma in two acutely infected individuals
Sample ID Total number of sequences
Maximum 
length of se-
quence
Maximum 
HD
Mean 
HD 
(%)
Poisson estimated 
days since MRCA 
Lamda (95% CI)
Lamda Standard Deviation
Good-
ness of fit 
P-value
HD fit to 
Poisson
Star 
phylog-
eny
T8250 
DBS
21 2556 6 1.60 27 (17, 37) 1.624 0.293 0.246 Yes Yes
T8250 
plasma
19 2557 6 1.70 28 (20, 35) 4.684 0.229 0.307 Yes No
N8261 
DBS
11 2559 2 0.36 6 (0, 12) 0.364 0.177 0.656 Yes Yes
N8261 
plasma
12 2560 4 1.20 19 (9, 30) 1.167 0.316 0.856 Yes Yes
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Identification of a single HIV-1 TF gp160 env gene using either DBS or plasma. We next 
examined the feasibility of using DBS as an alternative sample matrix to infer the TF HIV-1 env 
gene sequence. Figure 2 depicts Highlighter plots of the SGA-derived gp160 env sequences from 
DBS and plasma from 2 acutely infected subjects. In Figure 2A and B, the sequences from subject 
T8250 demonstrate similar low diversity lineages for DBS and plasma-derived sequences, which 
coalesce into a single, identical consensus sequence that represents the TF env. The DBS and plas-
ma sequences each demonstrate random mutations as well as two sites of shared polymorphisms 
(a synonymous mutation at HXB2 position 6881 and a non-synonymous mutation at position 
7279), which likely represent early stochastic mutations or selection. Importantly, they are at iden-
tical positions in the DBS and plasma derived sequences. Sequences from Subject N8261 (Figure 
2C, D) also demonstrate low-diversity lineages with largely identical sequences that coalesce to a 
single, shared TF env sequence for both DBS and plasma sequence sets. Thus, for both subjects, a 
low-diversity lineage coalesces to an unambiguous consensus sequence that is identical for DBS 
and plasma sequences. Importantly, as predicted for all TF viruses [4], the deduced amino acid 
sequence of the inferred consensus env gene corresponding to subjects T8250 and N8261 had 
intact open reading frames for the env gene and partial sequences coding for tat, rev, and vpu 
genes. Of interest, in both subjects the DBS sequences had a higher proportion of identical se-
quences (38% vs 29% and 73% vs 58%, for T8250 and N8261, respectively), a trend towards lower 
estimated time to MRCA (27 vs 28 days for T825 and 6 vs 19 for N8261, with overlapping 95% 
CI), and better conformed to a model of random virus replication in acute HIV-1 infection when 
compared to plasma sequences (Table 3) [4, 43]. Strong inter-assay reproducibility was observed 
in the SGA sequences generated for the two acutely infected individuals. For both T8250 and 
N8261, SGA was performed in multiple independent sessions, each of which yielded the identical 
amino acid TF sequence. 
Identification of the full-length HIV TF genome by SGA and next generation sequencing 
from DBS. We aimed to infer the complete nucleotide sequence of the TF HIV-1 virus in paired 
DBS-plasma samples. SGA analysis of 5′-half (n = 12), 3′-half (n = 5), and near-full length 9 Kb 
(n = 2) genomes generated from DBS or plasma coupled with the larger set of gp160 env sequenc-
es allowed the identification of the full-length TF HIV-1 genome in subject T8250 (Figure 3A). 
Half-genome sequences showed a Poisson distribution of mutations coalescing to a single con-
sensus. Shared polymorphisms seen in the env gene region were resolved by using the larger set of 
env-only sequences; there were no additional shared polymorphisms outside the env gene. 5′-half 
genome sequences were highly homogeneous and had no ambiguous positions, thus allowing 
the identification of the full-length TF genome of subject T8250. Highlighter analysis of 5′-half 
(n = 17) and 3′-half (n = 19) HIV-1 genome sequences from subject N8261 also revealed a Pois-
son distribution of mutations (Figure 3B) which, together with the gp160 env sequences, allowed 
inference of the identical single transmitted/founder HIV-1 genome using sequences from both 
DBS and plasma. 
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Figure 2. HIV-1 env sequences from paired DBS-plasma samples coalesce to a common ancestor in 
two acutely infected subjects. Highlighter plots of gp160 env sequences derived from DBS (red circles) or 
plasma (blue squares) from subjects T8250 (A) and N8261 (B) exhibit low genetic diversity and coalesce to 
identical TF env sequences for each subject. In T8250, shared polymorphisms occur at the same two nucle-
otide positions in both DBS and plasma sequences. Nucleotide differences from the inferred consensus se-
quence are indicated by tic marks color-coded for each base or gaps due to nucleotide deletions; tics inside 
brackets indicate nucleotide insertions. The horizontal axis indicates HXB2 env nucleotide positions. 
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Figure 3. Comparison of whole HIV-1 genomes from DBS by SGA and deep sequencing in two acute-
ly infected subjects. Half- and full-genome HIV-1 sequences derived from DBS (red circles) and plasma 
(blue squares) from subjects T8250 (A) and N8261 (B) are aligned to a patient-specific consensus mas-
ter sequence from SGA sequences (top line), gp160 env sequences (second line from top), and 454 deep 
sequences (third line). Colored tics and brackets are as defined in Figure 2. Flanking gray boxes indicate 
regions not amplified, while gray tics indicate intergenomic deletions. The horizontal axis indicates nucle-
otide positions based on HXB2 reference sequence numbering. The HIV-1 genome cartoon at the bottom 
depicts the flanking LTRs and 9 canonical protein-coding genes.
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We next assessed the capacity for DBS samples to be used in a next-generation sequencing (NGS) 
approach to identify the TF genome. With greater sequencing depth than standard SGA, NGS has 
improved sensitivity to detect minor variants (see sensitivity analysis in [4]). A direct comparison 
of a T8250 HIV-1 consensus sequence built from NGS sequencing reads (HXB2 positions: 501–
9606) showed a 100% match with the consensus inferred by SGA of DBS and plasma (Figure 3A). 
Nucleotide polymorphisms are shown in heat map format in Figure 4, and demonstrate that the 
vast majority of codon sites exhibited low diversity, with the minor variant generally comprising 
less than 10% of reads. In particular, the two shared polymorphisms in the env gene detected by 
SGA were also observed by NGS at modestly higher frequencies. 
Figure 4. 454 deep sequencing of TF HIV-1 progeny in two subjects with acute infection. Heat maps 
illustrate both non-synonymous and synonymous codon sequence diversity of HIV-1 from DBS RNA 
in subjects T8250 (A) and N8261 (B). The plots are a graphical representation of the frequency of the 
intra-host sequence diversity with respect to the dominant codon residue (% diversity) for each codon 
(x-axis) of individual canonical HIV-1 proteins (y-axis). Each square represent a single codon, colored to 
reflect the percentage of reads that differ from the consensus residue. The diversity scale is color-coded 
with completely conserved residues in black and marine-blue tones for low-frequency polymorphisms in 
codons (< 10%), sky-blue tones for those with moderately high frequency (10–30%) and green for high 
frequency polymorphisms (> 30%). The entire HIV-1 proteome of subject T8250 is represented in the up-
per plot, whereas the pol, gag, and env proteins are depicted for patient N8261 in the lower plot. Coverage 
plots depicting the coverage (sequencing reads per site, black line) and the level of variation (gray bars) at a 
given codon across the sequenced region of the genome are shown for subjects T8250 (C) and N8261 (D). 
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The GCC to GCT synonymous mutation at HXB2 position 6881 occurred in 38% of 336 high 
quality deep sequencing reads and 19% (4 out of 21) of SGA-derived env sequences from DBS, 
while the CAA to CGA non-synonymous mutation at position 7279 occurred in 48% of 509 
deep sequencing reads (shown in green on the heatmap in Figure 4A) and 14% (3 out of 21) of 
SGA-derived env sequences. A third shared polymorphism detected in 23% of deep sequencing 
reads (547 HQ read depth) in the vpu gene (HXB2 position 6072) was observed in 25% (1 out of 
4) of 3′-half sequences from DBS. Four additional shared polymorphisms that were not sampled 
by SGA were detected by NGS at frequencies ranging from 6% to 21% in the gag/pol region (HQ 
read depth range: 164–712) (Figure 4C). In N8261, the consensus sequence constructed from 
NGS sequencing reads showed a 99.96% match with the consensus sequence inferred by SGA 
of DBS and plasma (Figure 3B) with only 3 nucleotide differences in pol distinguishing the 2 
methods. For the 3 nucleotide discrepancies, the number of NGS quality reads was relatively low 
(< 100) (Figure 4D) and the SGA consensus bases were observed, but represented minor variants 
(frequency of 31–35%). Finally, as predicted, the inferred TF genome of the virus in both T8250 
and N8261 coded for an intact viral proteome for all major canonical HIV-1 proteins. 
DISCUSSION
In the present study, we tested the feasibility of using DBS to amplify full-length HIV-1 env genes 
by SGA and deep sequencing to assess sequence diversity in chronic infection and identify the 
full-length TF HIV-1 genome (or env gene) in recently infected individuals. We found that SGA 
from vRNA extracted from matched DBS and plasma were phylogenetically indistinguishable 
in representing the diversity of chronic HIV-1 quasispecies. This demonstration suggests that 
sophisticated sequence analyses are possible in research subjects and clinical trial participants 
throughout the world, including those sampled in locations far from a centralized laboratory 
facility. We also found that sequences from matched DBS and plasma samples identified a single 
TF virus with an identical env gene and full-length HIV-1 genome sequences by SGA and deep 
sequencing methodologies. Our study provides proof of concept that DBS can be used for both 
SGA and deep sequencing methods that form the cornerstone of modern molecular virology 
research. 
While less efficient than sequencing vRNA extracted from plasma that is flash frozen and stored 
at −80ºC, vRNA yields from DBS are sufficient for the vast majority of viral analyses currently em-
ployed, including identification of the complete TF genome. For env analyses, each DBS yielded 
between 4 and > 20 gp160 env sequences. Given the 5 DBS per typical commercially available DBS 
card and the potential to relatively easily collect multiple cards per subject at one time, the 10–30 
sequences generally used to infer the TF virus [1-5, 14, 15], are achievable. Similar numbers of 
sequences would be adequate to measure other viral parameters, including the characterization 
of the complex viral populations that could break through a suppressive and/or curative therapy 
and characterization of the HIV-1 quasispecies in an actively viremic individual off antiretroviral 
therapy.
Our analysis found that the efficiency of SGA from DBS was dependent on several factors, includ-
ing the RNA extraction method and storage time and temperature. We utilized a fairly standard 
vRNA isolation procedure to achieve sufficient yields to perform SGA; expectedly, variations on 
this protocol altered the efficiency of this process. As demonstrated in a recent study by Monleau 
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and colleagues [40], additional RNA isolation assay optimization could increase efficiency fur-
ther. As expected, we found that nucleic acid degradation occurred with DBS stored for weeks 
at ambient temperatures and, to a lesser extent, for months at −20ºC. The fact that storage of a 
single DBS sample for just 1 day at ambient temperature showed the highest efficiency in env 
amplification (41% using a TRIzol-alone protocol) compared to the significant lower efficiencies 
after 6–20 days of storage (Table 2) suggest that either prompt processing or immediate transfer of 
DBS cards to −20°C should result in higher PCR yields. The latter is supported by the observation 
that DBS placed at −20ºC within three weeks of collection preserved 19.4% to 88.9% of the RNA 
molecules remaining intact after the initial storage at ambient temperature, and those placed in 
freezers earlier (within a week) were even better preserved (Table 2). Further, DBS cards stored 
for months in non-frost-free −20ºC freezers maintained much of their viability. Though we do not 
expect RNA degradation to be biased towards any particular RNA populations and do not suspect 
it would affect phylogenetic patterns, we did not directly test this. The World Health Organiza-
tion recommends ≤ 14 days at ambient temperature after collection of DBS, which are then stored 
at −20ºC or −80ºC for monitoring HIV-1 drug resistance [28, 44]; this protocol would similarly 
maintain viability for SGA. A limitation of our study was the lack of assessment of the effects of 
the warm, humid conditions experienced in many tropical field settings. While this has decreased 
the efficiency of DBS-based assays in other studies [27, 45-47], we note the recent report from 
Zambia demonstrating successful PCR amplification of the HIV-1 DNA template from DBS [29]. 
While Seu and colleagues did not report sequencing results, their results strongly suggest that 
PCR and SGA are feasible in resource-limited field settings, though additional, larger field studies 
are warranted. 
Several findings from the comparisons of matched DBS and plasma-derived acute HIV sequences 
suggest that our DBS sequences represent a mixture of plasma HIV-1 RNA and cell-associated 
proviral DNA (or cell associated RNA). To begin, we found that plasma viral load measurements 
did not correlate with the efficiency of SGA. Indeed, samples with orders of magnitude differ-
ences in plasma viral load had relatively similar efficiencies in gp160 env amplification (Table 2). 
Further, compared to acute plasma-derived sequences, matched DBS sequences showed a trend 
towards greater identity with the TF virus and lower estimates of time to MRCA (Table 3). Cell-
free HIV-1 plasma virions have remarkably short half-lives (< 1 day) [48] and represent only the 
most recent rounds of viral replication. Cellular proviral DNA or cellular RNA, in contrast, may 
represent longer-lived virus sequences from replication cycles occurring days to weeks earlier. 
These more archival sequences therefore lack the additional random polymorphisms that accrue 
over time and are genetically closer to the TF virus. The discordance between plasma viral load 
and SGA sequence yield coupled with more ancestral (more TF-like virus) populations sampled 
by DBS suggest that DBS contain both plasma vRNA and proviral DNA. While we used a nucleic 
acid isolation protocol designed to preferentially extract RNA over DNA, it is likely that a certain 
amount of proviral DNA was also isolated. The presence of proviral DNA in DBS is well estab-
lished [22, 28]; a recent study by Masciotra and colleagues employing nonspecific nucleic acid 
extraction techniques found that as many as half of tested samples had amplifiable proviral DNA, 
with greater frequencies (up to 58%) in samples with higher plasma viral loads [22]. In addition, 
storage at ambient temperature may lead to degradation of the less stable vRNA and relative 
overrepresentation of DNA [27, 45-47]. Interestingly, increased representation of HIV DNA 
may actually be advantageous for TF identification. SGA of plasma vRNA and proviral DNA 
Pathogens and Immunity - Vol 1, No 1
www.PaiJournal.com
145
have been validated as equally able to identify the TF virus in acute samples [5] and the ability 
to amplify sequences representing earlier viral populations is beneficial to TF virus inference. In 
clinical specimens with low viral loads in chronically infected individuals, whose proviral DNA 
may reflect archived or defective virus, DNase treatment of DBS extracts should be considered to 
better reflect actively replicating plasma viral RNA [47].
As expected in the complex chronic HIV quasispecies, which are substantially more diverse and 
responding to multiple selective immune responses, subtle differences in timing between free 
plasma virus and cell-associated virus were not detected. Phylogenetically, paired DBS-plasma 
samples were highly similar; in fact, identical sequences from DBS and plasma were identified in 
several patients (Figure 1) and suggest that DBS and plasma are relatively equivalent specimens 
with which to characterize the circulating chronic HIV-1 viral quasispecies. Thus, we conclude 
that RNA-targeting nucleic acid isolation from DBS results in vRNA and some fraction of proviral 
DNA or cell-associated RNA that are less represented in acellular plasma. Importantly, this DNA 
does not alter the capacity for DBS to be used to accurately identify the TF virus and/or charac-
terize chronic viral quasispecies. This conclusion echoes similar findings from previous studies 
of DBS-based assessments of clinically relevant HIV parameters, including plasma viral load and 
genotypic drug resistance, wherein subtle differences between matched DBS and plasma assays 
were attributed to contributions from DNA, but results from the matched samples were largely 
equivalent (reviewed in [21]). 
In summary, this study demonstrates the feasibility of DBS as specimens for TF identification and 
viral diversity analyses in general. DBS provides significant cost savings and logistical advantages 
over standard plasma specimens. The capacity to utilize DBS in technically demanding molecular 
virology techniques expands opportunities for comprehensive and sophisticated studies in clinical 
trials and translational research to resource-limited settings across the world, including places 
where HIV-1 is most prevalent and intervention is most critical.
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SUPPLEMENTARY MATERIALS
Supplementary Figure 1. Maximum-likelihood phylogenetic tree of all study participants. The 9 study 
subjects’ SGA-derived gp160 env sequences cluster independently, demonstrating a lack of cross-contami-
nation. Sequences are color-coded by subject. Genetic distance is indicated by the scale bar.
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Intra-patient env sequence diversity
Two-sample test for  
sequence diversity
Slatkin-Maddison 
Test
 
Group
Number of 
sequences
Median Q1 a Q3 a IQR a T score:
Degrees of 
freedom:
Z-test P 
value:
T-test P 
value:
N-steps 
(S) b
P-value c
A8110 plasma 14 1.478 0.887 1.913 1.026 -1.588 33.23 0.112 0.122 12 0.968
DBS 16 1.078 0.590 1.480 0.890
K8072 plasma 8 0.611 0.504 0.759 0.256 -0.715 93.40 0.475 0.477 6 1
DBS 16 0.547 0.462 0.654 0.191
T4590 plasma 15 1.271 1.102 2.175 1.073 -1.669 2110.21 0.095 0.095 9 1
DBS 10 1.147 1.059 1.236 0.177
T8107 plasma 11 0.590 0.462 0.675 0.213 0.039 7.02 0.969 0.970 7 0.799
DBS 8 0.548 0.482 0.674 0.192
J7180 plasma 10 1.874 1.314 2.067 0.753 -0.581 0.84 0.561 0.680 6 0.432
DBS 9 1.484 1.145 2.150 1.005
J6161 plasma 6 1.189 0.932 1.402 0.470 0.294 0.58 0.768 0.841 5 0.712
DBS 9 1.316 0.826 1.661 0.835
F6817 plasma 12 0.715 0.589 0.842 0.254 -0.076 2.61 0.940 0.945 4 1
DBS 4 0.716 0.631 0.759 0.129
T8250 plasma 21 0.050 0.042 0.084 0.042 0.523 19.71 0.601 0.607 13 0.321
DBS 21 0.042 0.042 0.126 0.084
N8261 plasma 12 0.000 0.000 0.042 0.042 -0.314 52.45 0.753 0.755 8 0.645
DBS 11 0.000 0.000 0.042 0.042
Supplementary Table 1. HIV-1 env diversity and compartmentalization tests between two viral populations (plasma vs DBS) a) Rank-ordered di-
versity data were divided into four equal parts using quartiles: first (Q1), third (Q3) quartiles and interquartile range (IQR = Q3-Q1) are shown as a 
measure of variability. b) S denotes the number of changes (in parsimony steps) of a character corresponding to population membership.c) Proba-
bilty of S or fewer steps in 1,000 randomized tree assignments.
